DE LORENZO, CLAUDIA
 Distribuzione geografica
Continente #
NA - Nord America 1.861
EU - Europa 941
AS - Asia 311
AF - Africa 50
SA - Sud America 3
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.169
Nazione #
US - Stati Uniti d'America 1.830
IT - Italia 403
CN - Cina 237
NL - Olanda 123
IE - Irlanda 106
FI - Finlandia 88
UA - Ucraina 86
DE - Germania 55
CI - Costa d'Avorio 49
SE - Svezia 45
IN - India 43
CA - Canada 30
GB - Regno Unito 20
VN - Vietnam 12
SG - Singapore 7
ES - Italia 4
BR - Brasile 3
FR - Francia 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AU - Australia 2
BE - Belgio 2
CH - Svizzera 2
IR - Iran 2
KR - Corea 2
TR - Turchia 2
EU - Europa 1
HK - Hong Kong 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
PA - Panama 1
RO - Romania 1
ZA - Sudafrica 1
Totale 3.169
Città #
Chandler 427
Amsterdam 123
Naples 123
Jacksonville 112
Ashburn 104
Millbury 96
Princeton 90
Boston 74
Napoli 62
Nanjing 61
Beijing 55
Wilmington 43
Houston 38
Woodbridge 31
Pune 30
Ottawa 27
Des Moines 26
Cagliari 24
Nanchang 22
Falls Church 18
Kronberg 17
Lawrence 17
Shenyang 17
Boardman 15
Jiaxing 14
Dong Ket 12
Hebei 11
Norwalk 11
Perugia 11
Kunming 10
Acerra 8
Hyderabad 8
Seattle 8
Tianjin 8
Washington 8
Changsha 7
Jinan 7
Shanghai 7
Hangzhou 6
Ann Arbor 5
Caserta 4
Dublin 4
Marano di Napoli 4
Rome 4
Belgrade 3
Bergamo 3
Guangzhou 3
Indiana 3
Redwood City 3
Trentola-Ducenta 3
Villaricca 3
Bagheria 2
Bernalda 2
Casavatore 2
Changchun 2
Frankfurt am Main 2
Gravelines 2
Indore 2
Ischia 2
Lappeenranta 2
Marano 2
Marcianise 2
Milan 2
Orange 2
Padula 2
Portici 2
Pozzuoli 2
Quartu Sant'elena 2
Riva Del Garda 2
Sydney 2
São Paulo 2
Walnut 2
Winthrop 2
Agropoli 1
Aprilia 1
Ariano Irpino 1
Augusta 1
Aversa 1
Bath 1
Brindisi 1
Brussels 1
Bucharest 1
Camerino 1
Cerdanyola del Vallès 1
Corropoli 1
Curitiba 1
Dearborn 1
Edinburgh 1
Elora 1
Enna 1
Fairfield 1
Formia 1
Fremont 1
Gondomar 1
Jinhua 1
Kwangju 1
Lanzhou 1
Liedekerke 1
Livorno 1
London 1
Totale 1.901
Nome #
Nuovi agenti con attività antitumorale nei tumori ErbB2-positivi 64
A novel fully human antitumor ImmunoRNase targeting ErbB2-positive tumors 57
A novel fully human Antitumor ImmunoRNase targeting ErbB2-positive tumors 56
Ranolazine attenuates trastuzumab-induced heart dysfunction by modulating ROS production 54
A novel ErbB2 epitope targeted by Human antitumor Immunoagents 52
Novel human anti-Claudin 1 monoclonal antibodies inhibit HCV infection and may synergize with anti-SRB1 mAb. 50
A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. 48
A study of the Intracellular Routing of Cytotoxic Ribonucleases 47
A new human antitumor immunoreagent specific for ErbB2 47
A DIMERIC MUTANT OF HUMAN PANCREATIC RIBONUCLEASE WITH SELECTIVE CYTOTOXICITY TOWARD MALIGNANT CELLS 47
Novel Human Anti-ErbB2 Immunoagents 45
A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells. 44
Esiste la possibilità di ipotizzare un blocco dei recettori HER con immunoagenti senza effetti cardiotossici? 44
A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent 41
A dimeric mutant of human pancreatic ribonuclease with selective cytotoxicity towards malignant cells 40
Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin 40
Biological properties of a human compact anti-ErbB2 antibody. 40
Fusion protein comprising three binding domains to HER2 40
Methods and compositions relating to Anti-nucleolin recombinant immunoagents 40
Immunotoxins and ImmunoRNases 39
Effects of three different anti-ErbB2 antibodies on prostate tumors 39
Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer 38
Long-chain polyphosphates impair SARS-CoV-2 infection and replication 38
Anti-ErbB2 human Immunoagents 37
Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. 37
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries 37
Human Antitumor RNases and ImmunoRNases 36
One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1 36
Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking 36
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2 36
Novel Human Anti-ErbB2 Immunoagents 35
Bovine Seminal RNase: an atypical member of the ribonuclease superfamily 35
Thermodynamic stability of the two isoforms of bovine seminal ribonuclease. 34
Effects of a human compact anti-ErbB2 antibody on prostate cancer 34
Human anti-nucleolin recombinant immunoagent for cancer therapy 34
Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells 34
Human mini-antibody cytotoxic for tumor cells which express the ErbB2 receptor 33
Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent. 33
The molecular basis for the production of an antitumor protein 33
A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells 33
Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. 33
Crystal Structure of the Dimeric unswapped Form of Bovine Seminal Ribonuclease 31
Anti-ErbB2 human immunoagents 31
IMMUNORNASES AS ANTITUMOUR AGENTS 31
A Novel Human Anti-tumor Dimeric ImmunoRNase 31
A novel fully human antitumor ImmunoRNase resistant to the RNase inhibitor. 31
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing 31
Anti-ErbB2 Human Immunoagents 30
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours. 30
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. 30
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. 30
Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation. 30
Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab 30
Interactions of spike‐rbd of sars‐cov‐2 and platelet factor 4: New insights in the etiopathogenesis of thrombosis 30
Evaluation of the antiproliferative effect of Bifidobacterium longum BB-536 in solid tumor cell lines, co-cultured with murine splenocytes 30
Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC 30
Binding of human immunoagents and Herceptin to the ErbB2 receptor 29
DOXORUBICIN-INDUCED CARDIOTOXICITY IN MICE IS PREVENTED BY LATE INA INHIBITION WITH RANOLAZINE, WITH IMPROVEMENT IN HEART FUNCTION, FIBROSIS AND APOPTOSIS 29
8th International Meeting on Ribonucleases 28
Antitumor pancreatic-type RNases 28
Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies? 28
Cardioprotection induced by ranolazine after trastuzumab treatment: the reduction of cardiotoxicity in vitro and in vivo study 28
Anti-ErbB2 immunoagents 27
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents 27
Human, Anti-ErbB2 Antitumor Immunoagents 26
Inhibition of cardiomyocytes late I-Na with ranolazine blunts anthracyclines-cardiotoxicity in experimental models in vitro and in vivo 26
T-cell Activating Tribodies as a Novel Approach for Efficient Killing of ErbB2-positive Cancer Cells. 26
A Novel Human Neutralizing mAb Recognizes Delta, Gamma and Omicron Variants of SARS-CoV-2 and Can Be Used in Combination with Sotrovimab 25
The singular case of seminal RNase, a dimer with two quaternary conformations, inspected with Trypsin as a conformational probe 25
Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents 25
Effects of protein RNase inhibitor and substrate on the quaternary structures of bovine seminal RNase 25
Effects of a human compact anti-ErbB2 antibody on gastric cancer. 25
Filamentous Phage Display 24
NUOVI IMMUNOAGENTI UMANI ANTI-ERBB2 24
Fully Human Anti-Cancer ImmunoAgents 24
Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody 24
Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model 23
From immunotoxins to immunoRNases. 23
NOVEL HUMAN ANTI-ErbB2 IMMUNOAGENTS 23
RANOLAZINE AT THE END OF TRASTUZUMAB THERAPY PREVENTS LEFT VENTRICULAR DYSFUNCTION: IN VITRO AND IN VIVO STUDY 23
High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand 23
Trypsin sheds light on the singular case of seminal RNase, a dimer with two quaternary conformations. 22
The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane. 22
COMPARISON OF CARDIOTOXIC EFFECTS OF DIFFERENT ERB-B2 INHIBITORS AND THEIR ASSOCIATED MECHANISMS 22
A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy 22
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling 22
Crystallization of multiple forms of bovine seminal ribonuclease in the liganded and unliganded state 21
Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells 21
Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge 20
ImmunoRNases as antitumor agents 20
Selective and asymmetric action of trypsin on the dimeric forms of seminal Rnase. 19
First and Second Generation Human anti-ErbB2 Immunoagents 19
Differential binding of human immunoagents and Herceptin to the ErbB2 receptor 19
The antitumor action of seminal ribonuclease and its quaternary conformations 18
Evidences of CTLA-4 and PD-1 blocking agents-induced cardiotoxicity in cellular and preclinical models 18
Immunomodulatory mabs as tools to investigate on cis-interaction of pd-1/pd-l1 on tumor cells and to set up methods for early screening of safe and potent combinatorial treatments 18
Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo 17
Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of Ranolazine 17
New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC 16
Ranolazine blunts anthracyclines-cardiotoxicity in experimental models in vitro and in vivo. 16
Totale 3.139
Categoria #
all - tutte 12.664
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.664


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201921 0 0 0 0 0 0 0 0 0 0 2 19
2019/2020301 109 0 21 4 37 1 8 3 4 27 49 38
2020/2021265 6 18 41 22 23 39 19 5 21 23 32 16
2021/2022704 4 4 2 3 12 16 22 34 122 48 194 243
2022/20231.010 124 77 31 86 123 118 5 85 171 116 57 17
2023/2024567 27 112 128 47 30 92 22 107 1 1 0 0
Totale 3.339